Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Forum Financial Management LP

Forum Financial Management LP grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 39.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 2,467 shares of the medical instruments supplier’s stock after purchasing an additional 692 shares during the quarter. Forum Financial Management LP’s holdings in Becton, Dickinson and Company were worth $595,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of BDX. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at $26,000. Sound Income Strategies LLC increased its position in shares of Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Opal Wealth Advisors LLC acquired a new position in shares of Becton, Dickinson and Company during the 2nd quarter valued at $45,000. Abound Wealth Management increased its position in shares of Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 96 shares during the period. Finally, Chilton Capital Management LLC boosted its stake in shares of Becton, Dickinson and Company by 1,233.3% during the 2nd quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 185 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

BDX opened at $234.33 on Tuesday. The stock has a market cap of $67.73 billion, a price-to-earnings ratio of 48.22, a PEG ratio of 1.75 and a beta of 0.43. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $259.92. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The stock has a fifty day moving average price of $237.52 and a 200 day moving average price of $235.10.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BDX. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Evercore ISI raised their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Stifel Nicolaus raised their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Raymond James decreased their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.